Cargando…
Evaluation of Safety and Immunogenicity of BNT162B2 mRNA COVID-19 Vaccine in IBD Pediatric Population with Distinct Immune Suppressive Regimens
Patients affected by Inflammatory Bowel Disease (IBD) present higher risk for infection and suboptimal response upon vaccination. The immunogenicity of SARS-CoV2 vaccination is still largely unknown in adolescents or young adults affected by IBD (pIBD). We investigated the safety and immunogenicity...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318731/ https://www.ncbi.nlm.nih.gov/pubmed/35891273 http://dx.doi.org/10.3390/vaccines10071109 |
_version_ | 1784755363137978368 |
---|---|
author | Cotugno, Nicola Franzese, Enrica Angelino, Giulia Amodio, Donato Romeo, Erminia Francesca Rea, Francesca Faraci, Simona Tambucci, Renato Profeti, Elisa Manno, Emma Concetta Santilli, Veronica Rotulo, Gioacchino Andrea Pighi, Chiara Medri, Chiara Morrocchi, Elena Colagrossi, Luna Pascucci, Giuseppe Rubens Valentini, Diletta Villani, Alberto Rossi, Paolo De Angelis, Paola Palma, Paolo |
author_facet | Cotugno, Nicola Franzese, Enrica Angelino, Giulia Amodio, Donato Romeo, Erminia Francesca Rea, Francesca Faraci, Simona Tambucci, Renato Profeti, Elisa Manno, Emma Concetta Santilli, Veronica Rotulo, Gioacchino Andrea Pighi, Chiara Medri, Chiara Morrocchi, Elena Colagrossi, Luna Pascucci, Giuseppe Rubens Valentini, Diletta Villani, Alberto Rossi, Paolo De Angelis, Paola Palma, Paolo |
author_sort | Cotugno, Nicola |
collection | PubMed |
description | Patients affected by Inflammatory Bowel Disease (IBD) present higher risk for infection and suboptimal response upon vaccination. The immunogenicity of SARS-CoV2 vaccination is still largely unknown in adolescents or young adults affected by IBD (pIBD). We investigated the safety and immunogenicity of the BNT162B2 mRNA COVID-19 vaccine in 27 pIBD, as compared to 30 healthy controls (HC). Immunogenicity was measured by anti-SARS-CoV2 IgG (anti-S and anti-trim Ab) before vaccination, after 21 days (T21) and 7 days after the second dose (T28). The safety profile was investigated by close monitoring and self-reported adverse events. Vaccination was well tolerated, and short-term adverse events reported were only mild to moderate. Three out of twenty-seven patients showed IBD flare after vaccination, but no causal relationship could be established. Overall, pIBD showed a good humoral response upon vaccination compared to HC; however, pIBD on anti-TNFα treatment showed lower anti-S Ab titers compared to patients receiving other immune-suppressive regimens (p = 0.0413 at first dose and p = 0.0301 at second dose). These data show that pIBD present a good safety and immunogenicity profile following SARS-CoV-2 mRNA vaccination. Additional studies on the impact of specific immune-suppressive regimens, such as anti TNFα, on immunogenicity should be further investigated on larger cohorts. |
format | Online Article Text |
id | pubmed-9318731 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93187312022-07-27 Evaluation of Safety and Immunogenicity of BNT162B2 mRNA COVID-19 Vaccine in IBD Pediatric Population with Distinct Immune Suppressive Regimens Cotugno, Nicola Franzese, Enrica Angelino, Giulia Amodio, Donato Romeo, Erminia Francesca Rea, Francesca Faraci, Simona Tambucci, Renato Profeti, Elisa Manno, Emma Concetta Santilli, Veronica Rotulo, Gioacchino Andrea Pighi, Chiara Medri, Chiara Morrocchi, Elena Colagrossi, Luna Pascucci, Giuseppe Rubens Valentini, Diletta Villani, Alberto Rossi, Paolo De Angelis, Paola Palma, Paolo Vaccines (Basel) Article Patients affected by Inflammatory Bowel Disease (IBD) present higher risk for infection and suboptimal response upon vaccination. The immunogenicity of SARS-CoV2 vaccination is still largely unknown in adolescents or young adults affected by IBD (pIBD). We investigated the safety and immunogenicity of the BNT162B2 mRNA COVID-19 vaccine in 27 pIBD, as compared to 30 healthy controls (HC). Immunogenicity was measured by anti-SARS-CoV2 IgG (anti-S and anti-trim Ab) before vaccination, after 21 days (T21) and 7 days after the second dose (T28). The safety profile was investigated by close monitoring and self-reported adverse events. Vaccination was well tolerated, and short-term adverse events reported were only mild to moderate. Three out of twenty-seven patients showed IBD flare after vaccination, but no causal relationship could be established. Overall, pIBD showed a good humoral response upon vaccination compared to HC; however, pIBD on anti-TNFα treatment showed lower anti-S Ab titers compared to patients receiving other immune-suppressive regimens (p = 0.0413 at first dose and p = 0.0301 at second dose). These data show that pIBD present a good safety and immunogenicity profile following SARS-CoV-2 mRNA vaccination. Additional studies on the impact of specific immune-suppressive regimens, such as anti TNFα, on immunogenicity should be further investigated on larger cohorts. MDPI 2022-07-11 /pmc/articles/PMC9318731/ /pubmed/35891273 http://dx.doi.org/10.3390/vaccines10071109 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Cotugno, Nicola Franzese, Enrica Angelino, Giulia Amodio, Donato Romeo, Erminia Francesca Rea, Francesca Faraci, Simona Tambucci, Renato Profeti, Elisa Manno, Emma Concetta Santilli, Veronica Rotulo, Gioacchino Andrea Pighi, Chiara Medri, Chiara Morrocchi, Elena Colagrossi, Luna Pascucci, Giuseppe Rubens Valentini, Diletta Villani, Alberto Rossi, Paolo De Angelis, Paola Palma, Paolo Evaluation of Safety and Immunogenicity of BNT162B2 mRNA COVID-19 Vaccine in IBD Pediatric Population with Distinct Immune Suppressive Regimens |
title | Evaluation of Safety and Immunogenicity of BNT162B2 mRNA COVID-19 Vaccine in IBD Pediatric Population with Distinct Immune Suppressive Regimens |
title_full | Evaluation of Safety and Immunogenicity of BNT162B2 mRNA COVID-19 Vaccine in IBD Pediatric Population with Distinct Immune Suppressive Regimens |
title_fullStr | Evaluation of Safety and Immunogenicity of BNT162B2 mRNA COVID-19 Vaccine in IBD Pediatric Population with Distinct Immune Suppressive Regimens |
title_full_unstemmed | Evaluation of Safety and Immunogenicity of BNT162B2 mRNA COVID-19 Vaccine in IBD Pediatric Population with Distinct Immune Suppressive Regimens |
title_short | Evaluation of Safety and Immunogenicity of BNT162B2 mRNA COVID-19 Vaccine in IBD Pediatric Population with Distinct Immune Suppressive Regimens |
title_sort | evaluation of safety and immunogenicity of bnt162b2 mrna covid-19 vaccine in ibd pediatric population with distinct immune suppressive regimens |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318731/ https://www.ncbi.nlm.nih.gov/pubmed/35891273 http://dx.doi.org/10.3390/vaccines10071109 |
work_keys_str_mv | AT cotugnonicola evaluationofsafetyandimmunogenicityofbnt162b2mrnacovid19vaccineinibdpediatricpopulationwithdistinctimmunesuppressiveregimens AT franzeseenrica evaluationofsafetyandimmunogenicityofbnt162b2mrnacovid19vaccineinibdpediatricpopulationwithdistinctimmunesuppressiveregimens AT angelinogiulia evaluationofsafetyandimmunogenicityofbnt162b2mrnacovid19vaccineinibdpediatricpopulationwithdistinctimmunesuppressiveregimens AT amodiodonato evaluationofsafetyandimmunogenicityofbnt162b2mrnacovid19vaccineinibdpediatricpopulationwithdistinctimmunesuppressiveregimens AT romeoerminiafrancesca evaluationofsafetyandimmunogenicityofbnt162b2mrnacovid19vaccineinibdpediatricpopulationwithdistinctimmunesuppressiveregimens AT reafrancesca evaluationofsafetyandimmunogenicityofbnt162b2mrnacovid19vaccineinibdpediatricpopulationwithdistinctimmunesuppressiveregimens AT faracisimona evaluationofsafetyandimmunogenicityofbnt162b2mrnacovid19vaccineinibdpediatricpopulationwithdistinctimmunesuppressiveregimens AT tambuccirenato evaluationofsafetyandimmunogenicityofbnt162b2mrnacovid19vaccineinibdpediatricpopulationwithdistinctimmunesuppressiveregimens AT profetielisa evaluationofsafetyandimmunogenicityofbnt162b2mrnacovid19vaccineinibdpediatricpopulationwithdistinctimmunesuppressiveregimens AT mannoemmaconcetta evaluationofsafetyandimmunogenicityofbnt162b2mrnacovid19vaccineinibdpediatricpopulationwithdistinctimmunesuppressiveregimens AT santilliveronica evaluationofsafetyandimmunogenicityofbnt162b2mrnacovid19vaccineinibdpediatricpopulationwithdistinctimmunesuppressiveregimens AT rotulogioacchinoandrea evaluationofsafetyandimmunogenicityofbnt162b2mrnacovid19vaccineinibdpediatricpopulationwithdistinctimmunesuppressiveregimens AT pighichiara evaluationofsafetyandimmunogenicityofbnt162b2mrnacovid19vaccineinibdpediatricpopulationwithdistinctimmunesuppressiveregimens AT medrichiara evaluationofsafetyandimmunogenicityofbnt162b2mrnacovid19vaccineinibdpediatricpopulationwithdistinctimmunesuppressiveregimens AT morrocchielena evaluationofsafetyandimmunogenicityofbnt162b2mrnacovid19vaccineinibdpediatricpopulationwithdistinctimmunesuppressiveregimens AT colagrossiluna evaluationofsafetyandimmunogenicityofbnt162b2mrnacovid19vaccineinibdpediatricpopulationwithdistinctimmunesuppressiveregimens AT pascuccigiusepperubens evaluationofsafetyandimmunogenicityofbnt162b2mrnacovid19vaccineinibdpediatricpopulationwithdistinctimmunesuppressiveregimens AT valentinidiletta evaluationofsafetyandimmunogenicityofbnt162b2mrnacovid19vaccineinibdpediatricpopulationwithdistinctimmunesuppressiveregimens AT villanialberto evaluationofsafetyandimmunogenicityofbnt162b2mrnacovid19vaccineinibdpediatricpopulationwithdistinctimmunesuppressiveregimens AT rossipaolo evaluationofsafetyandimmunogenicityofbnt162b2mrnacovid19vaccineinibdpediatricpopulationwithdistinctimmunesuppressiveregimens AT deangelispaola evaluationofsafetyandimmunogenicityofbnt162b2mrnacovid19vaccineinibdpediatricpopulationwithdistinctimmunesuppressiveregimens AT palmapaolo evaluationofsafetyandimmunogenicityofbnt162b2mrnacovid19vaccineinibdpediatricpopulationwithdistinctimmunesuppressiveregimens |